Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by system...
Main Author: | Chana L. Glasser, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | Leukemia Research Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048917300420 |
Similar Items
-
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
by: Jing Chen, et al.
Published: (2020-02-01) -
A Scid mouse model of human acute myelogenous leukemia (AML)
by: Moore, Carolyn J. L.
Published: (2009) -
A Scid mouse model of human acute myelogenous leukemia (AML)
by: Moore, Carolyn J. L.
Published: (2009) -
Evaluation of Chemotherapy Toxicity in Acute Lymphoblastic and Myelogenous Leukemia
by: Taher Entezari-Maleki, et al.
Published: (2012-06-01) -
Evaluation of Chemotherapy Toxicity in Acute Lymphoblastic and Myelogenous Leukemia
by: Ardeshir Ghavamzadeh, et al.
Published: (2012-04-01)